University of Child Health Scienes Lahore
Lahore, Punjab Province, 52000, Pakistan
Location contact
IQRA Asghar Ali, mbbs
PRINCIPAL_INVESTIGATOR
Iqra Asghar Ali, mbbs
CONTACT
NCT Number: NCT07641348
This randomized controlled trial will compare the effectiveness of single-drug therapy (meropenem) versus combination therapy (meropenem plus azithromycin) in children aged 2-16 years diagnosed with extensively drug-resistant (XDR) typhoid fever at the Children's Hospital, Lahore. A total of 94 patients will be enrolled and randomly assigned to either treatment group. The primary outcome is time to defervescence, defined as sustained resolution of fever for more than 48 hours. Secondary outcomes include duration of hospital stay and complication rates. The study aims to provide evidence to guide optimal management of XDR typhoid in pediatric populations."
Trial opening soon.
Get Notified2 year–16 year
All sexes
Interventional
Not applicable
Lahore, Punjab Province, 52000, Pakistan
IQRA Asghar Ali, mbbs
PRINCIPAL_INVESTIGATOR
Iqra Asghar Ali, mbbs
CONTACT
Typhoid fever caused by Salmonella enterica serovar Typhi remains a major public health challenge in low- and middle-income countries. The emergence of extensively drug-resistant (XDR) strains, resistant to first-line agents, fluoroquinolones, and third-generation cephalosporins, has severely limited treatment options. In Pakistan, outbreaks of XDR typhoid have been reported since 2016, with thousands of confirmed cases in Karachi and Hyderabad. Current guidelines recommend carbapenems and azithromycin as the remaining effective agents, but the optimal regimen remains uncertain.
This randomized controlled trial will compare single-drug therapy (meropenem) with combination therapy (meropenem plus azithromycin) in pediatric patients aged 2-16 years with culture-confirmed XDR typhoid fever admitted to the Children's Hospital, Lahore. Ninety-four patients will be enrolled and randomly assigned to either treatment group using concealed allocation. Meropenem will be administered intravenously at 30 mg/kg/dose every 8 hours(maximum 2g per dose)while azithromycin will be given orally at 20 mg/kg/day according to hospital protocol. The primary endpoint is time to defervescence, defined as sustained resolution of fever for more than 48 hours. Secondary endpoints include duration of hospital stay and complication rates.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Informed consent obtained from parent/guardian
Exclusion criteria
IV meropenem, 100 mg/kg/day TDS
combination drug therapy will consist of meropenem intravenously at a dose of 20-40 mg/kg/dose every 8 hours(maximum 2g per dose) plus azithromycin (orally) at 20 mg/kg/day
Time frame: Time Frame: 10-14days after initiation of treatment
Description: Number of days from initiation of appropriate antimicrobial therapy until sustained resolution of fever (<100°F for >48 hours).
Contact information is provided by the study sponsor or research team.
Iqra Asghar Ali
Other
COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG-RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06757283
Bacterial Infections, Bacterial Infections and Mycoses
Dhaka, Bangladesh
View Trial DetailsNCT05500482
Bacterial Infections, Bacterial Infections and Mycoses
Vellore, Tamil Nadu, India
View Trial DetailsNCT07445282
Bacterial Infections, Bacterial Infections and Mycoses
Rahim Yar Khan, Punjab Province, Pakistan
View Trial DetailsNCT04349826
Bacterial Infections, Bacterial Infections and Mycoses
Lalitpur, Bagmati, Nepal
View Trial Details